Article Sidebar

PDF
Date Published: 28/06/2025
Abstract Views: 3
Views PDF: 4
DOI: https://doi.org/10.56535/jmpm.v50i5.1239
Issue
Vol. 50 No. 5 (2025): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 5 - 2025
Section
Articles
How to Cite
Phương, N. A., Đinh, V. L., Nguyễn, Đ. H., Nguyễn, V. B., & Hồ, H. T. (2025). DIAGNOSTIC VALUE OF SHOX2 METHYLATION IN PLASMA FOR NON-SMALL CELL LUNG CANCER. Journal of Military Pharmaco-medicine, 50(5), 88-96. https://doi.org/10.56535/jmpm.v50i5.1239

DIAGNOSTIC VALUE OF SHOX2 METHYLATION IN PLASMA FOR NON-SMALL CELL LUNG CANCER

Ngọc Anh Phương1, Văn Lượng Đinh1, Đức Hạnh Nguyễn1, Văn Ba Nguyễn2, Hữu Thọ Hồ3,4,
1 Bệnh viện Phổi Trung ương
2 Bệnh viện Quân y 175
3 Phòng Công nghệ Gene & Di truyền, Viện Nghiên cứu Y Dược học Quân sự, Học viện Quân y
4 Bộ môn Vi sinh vật, Bệnh viện Quân y 103, Học viện Quân y

Main Article Content

Abstract

Objective: This study evaluates the methylation status of SHOX2 (mSHOX2) in peripheral blood and its diagnostic value for non-small cell lung cancer (NSCLC). Methods: Blood samples from 149 NSCLC patients and 100 healthy individuals were analyzed using semi-nested quantitative methylation-specific PCR (sqMSP). Diagnostic performance was assessed using ROC curve analysis and multivariate logistic regression. Results: mSHOX2 ΔCt was significantly lower in NSCLC patients than in healthy controls (p < 0.001), indicating higher methylation levels. ROC analysis showed AUC = 0.715, sensitivity 56.38%, and specificity 82.00%. Multivariate logistic regression confirmed that mSHOX2, age, and BMI were independent factors associated with NSCLC risk, while gender and smoking history were no longer significant after adjustment. Conclusion: mSHOX2 is a promising non-invasive biomarker for NSCLC detection. Further studies are needed to enhance diagnostic accuracy by integrating additional biomarkers.

Article Details

Keywords

SHOX2 methylation, lung cancer, biomarker, liquid biopsy, methylation-specific PCR

References

1. Siegel RL, Miller KD, & Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023; 73(1):17-48. https://doi.org/10.3322/caac.21763.
2. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine. 2011; 365(5):395-409. https://doi.org/10.1056/NEJMoa1102873.
3. Pinsky PF. Lung cancer screening with low-dose CT: A world-wide view. Transl Lung Cancer Res. 2018 Jun; 7(3):234-242. DOI: 10.21037/tlcr.2018. 05.12.
4. Herbst RS, Morgensztern D, & Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553:446-454. https://doi.org/ 10.1038/nature25183.
5. Schmidt B, Liebenberg V, Dietrich D et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer. 2010 Nov 3; 10:600. DOI: 10.1186/1471-2407-10-600.
6. Dietrich D, Kneip C, Raji O et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol. 2012 Mar; 40(3):825-832. DOI: 10.3892/ijo.2011.1264.
7. Weiss G, Schlegel A, Kottwitz D et al. Validation of the SHOX2/ PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J Thorac Oncol. 2017 Jan; 12(1):77-84. DOI: 10.1016/j.jtho.2016.08.123.
8. Phuong NA, Dao TT, Pham PB et al. Novel semi-nested real-time PCR assay leveraging extendable blocking probes for improved SHOX2 methylation analysis in lung cancer. Biomolecules 2024; 14: 729. https://doi.org/10.3390/ biom14060729.